Get express prescriptions in minutes
Refill Prescription UTI Birth Control STD ED Hair Loss Acne Allergies Asthma Malaria IBS Hemorrhoids Urinary Incontinence Conjunctivitis
Trustpilot
Trustpilot
Mobidoctor € 43
Avg weight loss clinic €200-2000

FAQ

Tirzepatide, the active component in Mounjaro, has emerged as one of the most efficient and dependable approaches to achieving rapid and safe weight loss. Clinical trials have demonstrated its ability to help individuals shed an average of up to 21% of their initial body weight when used with a reduced-calorie diet and increased physical activity, surpassing the results observed in placebo participants.

Mounjaro (tirzepatide) offers numerous advantages, encompassing notable benefits such as weight loss and improved management of diabetes symptoms. Clinical trials have demonstrated impressive weight loss outcomes, with participants experiencing around 20% or more reduction in body weight after a year of Mounjaro (tirzepatide) treatment. Moreover, this medication has proven to be effective in controlling the symptoms associated with diabetes.

Mounjaro (tirzepatide) by Eli Lilly is prescribed with diet and exercise for adults diagnosed with type 2 diabetes mellitus. Through clinical studies, once-weekly Ozempic (tirzepatide) has demonstrated its efficacy in reducing HbA1c levels (a long-term measure of blood sugar control) by up to 2.3% compared to baseline.

Mounjaro (tirzepatide) has demonstrated remarkable effectiveness as a weight-loss medication, with patients typically experiencing a weight reduction of 20% or more after one year of treatment. This novel medication is anticipated to surpass the efficacy of GLP-1 alone, making it a highly promising choice for individuals seeking safe and effective solutions for managing their weight.

What is Mounjaro (tirzepatide)?

Mounjaro, a weekly injectable medication, falls under the category of GLP-1 drugs, similar to Novo Nordisk's Wegovy.

While primarily used for patients with type 2 diabetes, Mounjaro also exhibits potential as a weight-loss medication.

Clinical trials have demonstrated the effectiveness of tirzepatide in reducing haemoglobin A1C levels and aiding in weight loss. Early data suggests that it may even contribute to a decreased risk of cardiovascular events like heart attacks or strokes, although a conclusive trial on this matter is still ongoing.

Mounjaro should be utilised with lifestyle modifications, such as dietary adjustments, improved sleep patterns, and regular exercise, to achieve optimal results. Professional coaching and expert support are expected to enhance the drug's efficacy.

The recommended initial dose of Mounjaro is 2.5 mg, with the option to gradually increase the dosage by 2.5 mg increments every four weeks, as long as it is well tolerated. The maximum weekly dose should not exceed 15 mg. Healthcare providers are responsible for prescribing and monitoring the appropriate dosage adjustments, aligning them with patients' blood sugar control, weight loss, and overall metabolic health objectives.

BOOK APPOINTMENT